Inhibrx Total Liab from 2010 to 2025
| INBX Stock | USD 14.35 0.25 1.77% |
Total Liabilities | First Reported 2019-03-31 | Previous Quarter 44.1 M | Current Value 47.2 M | Quarterly Volatility 83.3 M |
Check Inhibrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx's main balance sheet or income statement drivers, such as Interest Expense of 10.6 M, Minority Interest of 0.0 or Tax Provision of 1.9 K, as well as many indicators such as Price To Sales Ratio of 1.2 K, Dividend Yield of 0.0021 or PTB Ratio of 1.79. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Valuation or Volatility modules.
Inhibrx | Total Liab |
Latest Inhibrx's Total Liab Growth Pattern
Below is the plot of the Total Liab of Inhibrx over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Inhibrx's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibrx's overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Inhibrx Total Liab Regression Statistics
| Arithmetic Mean | 78,785,116 | |
| Geometric Mean | 61,634,202 | |
| Coefficient Of Variation | 89.68 | |
| Mean Deviation | 50,024,067 | |
| Median | 44,823,850 | |
| Standard Deviation | 70,654,173 | |
| Sample Variance | 4992T | |
| Range | 224.7M | |
| R-Value | 0.52 | |
| Mean Square Error | 3924.9T | |
| R-Squared | 0.27 | |
| Significance | 0.04 | |
| Slope | 7,656,426 | |
| Total Sum of Squares | 74880.2T |
Inhibrx Total Liab History
About Inhibrx Financial Statements
Inhibrx investors use historical fundamental indicators, such as Inhibrx's Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inhibrx. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 47.2 M | 44.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.